Annals of Oncology 11:679-684, 2000
© 2000 European Society for Medical Oncology
research-article |
Semen analysis and cryoconservation before treatment in Hodgkin's disease
1Bone Marrow Transplant Unit/Hospital Haut-Leveque Pessac
2Department of Hematology/Oncology, Institute Bergonié, Regional Cancer Center
3CECOS (Centre d'étude et de conservation des oeufset du sperme) Aquitaine: Maternité Hospital Pellegrin Bordeaux, France
Correspondence to: Dr H. Eghbali, Department of Hematology/Oncology, Institut Bergonié, Regional Cancer Center, 180, rue de Saint Genès, 33076 Bordeaux cedex, France, E-mail: eghbali{at}bergonie.org
Background: The prophylaxis of the late effects of chemotherapy and radiotherapy has become one of the major concerns in the management of Hodgkin's disease (HD). Unlike other complications, male sterility could be managed by prior semen preservation (SP).
Patients and methods: To evaluate the semen quality of patients with HD and the outcome of insemination, we reviewed spermograms of patients who underwent SP before any treatment. The following criteria were necessary: 1) age > 16 and < 50; 2) HD of any stage; 3) informed about male sterility after HD treatment; 4) fully consenting.
Results: Such a proposal was made to 316 men, and 94 fulfilled the criteria. All patients underwent an initial chemotherapy. Mean age of the cohort was 27.5 years (range 16–48 years). Pretherapeutic staging of HD revealed 38 stage I (40%), 38 II (38%), 14 III (15%) and 4 IV (4%). Semen analysis before cryoconservation showed an overall 53% of normal or subnormal cases (50 cases). The analysis of semen quality and spermatozoid amount according to various parameters failed to find a correlation with stage, B symptoms, age, or biologic data (LDH, WBC, platelets, ESR). The use of cryopreserved semen was requested by 13 patients; 88 inseminations were performed leading to 9 pregnancies and 2 births.
Conclusions: The low rate of success with cryopreserved semen in these cases suggests the need for a more careful design of non-toxic chemotherapy regimens in combined modality treatment.
cryopreservation, Hodgkin's disease, sterility
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. van den Berg, S. Repping, and F. van der Veen Parental desire and acceptability of spermatogonial stem cell cryopreservation in boys with cancer Hum. Reprod., February 1, 2007; 22(2): 594 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Behringer, K. Breuer, T. Reineke, M. May, L. Nogova, B. Klimm, T. Schmitz, L. Wildt, V. Diehl, and A. Engert Secondary Amenorrhea After Hodgkin's Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., October 20, 2005; 23(30): 7555 - 7564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Agarwal and S. S. R. Allamaneni Disruption of Spermatogenesis by the Cancer Disease Process J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gandini, F. Lombardo, P. Salacone, D. Paoli, A. P. Anselmo, F. Culasso, F. Dondero, and A. Lenzi Testicular cancer and Hodgkin's disease: evaluation of semen quality Hum. Reprod., April 1, 2003; 18(4): 796 - 801. [Abstract] [Full Text] [PDF]
|
|